WuXi Eyes Growing Biologics Business With New Integrated Center
This article was originally published in PharmAsia News
An integrated biologics solution center is China's largest CRO WuXi AppTec's first investment completes its going private move. Aiming to provide full range of services to clients developing antibody drugs, WuXi plans more investment within the next 12 months.
You may also be interested in...
WuXi Biologics is aiming high to become the world’s biggest biologics manufacturer within five years after seeing strong confidence from capital markets in its growth potential and a boost from its new biologics manufacturing facility. The Chinese company plans on more investment in early 2018 to prepare for an expected biologics surge in China, its chief executive tells Scrip.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.